Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $208,946.00 |
|---|---|
| Enterprise Value | $11.69 Million |
| Earnings per Share | $0.09 |
| Beta | 0.35 |
| Outstanding Shares | 1,229,096 |
| P/E Ratio | -0.01 |
|---|---|
| PEG | 0.05 |
| Price to Sales | - |
| Price to Book Ratio | -0.02 |
| Enterprise Value to Revenue | 10.18 |
| Enterprise Value to EBIT | -7.47 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.98 |
| Debt to Equity | -0.85 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized...